News | September 26, 2016

Versartis Initiates Phase 3 Trial of Somavaratan in Japan for Children with Growth Hormone Deficiency Following Completion of Phase 2 MENLO PARK, Calif., Sept. 26, 2016 (GLOBE NEWSWIRE) — Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical...

News | September 22, 2016

Truveris Strengthens Leadership Team with Appointment of Faisal Mushtaq as Chief Executive Officer Company seeks to make prescription drug ecosystem more efficient by providing transparency through data-driven solutions NEW YORK – THURSDAY, SEPTEMBER 22,...

News | September 15, 2016

Intarcia Completes First Close of a Major Equity Financing; Poised for ITCA 650 NDA Filing for Type 2 Diabetes, Commercial Readiness and Pipeline Progression First close secured subscriptions of $215 million, a second larger close is expected in 4Q; Company pleased...

News | September 15, 2016

Kit Check Adds Former QSI/NextGen Healthcare Sales Leader Gary Voydanoff as New Chief Commercial Officer Washington, DC – Kit Check, the leader in hospital pharmacy medication tracking software and drug spend optimization analytics, announced today that Gary...

News | September 12, 2016

Versartis Presents Data From Up to 30 Months of Somavaratan Treatment for Pediatric Growth Hormone Deficiency at the 2016 ESPE Annual Meeting MENLO PARK, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) — Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused...
quis dapibus ut dolor. ut id accumsan mattis